Phase 3 Colorectal cancer trials recruiting now

All Colorectal cancer trials, every phase

Other phases for Colorectal cancer

Phase 3 Colorectal cancer trials

• A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC)
  NCT04547166 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 5 locations
• A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in Locally Advanced Rectal Cancer
  NCT07113275 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer
  NCT07361003 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer
  NCT07462143 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 19 locations
• A Randomized, Double-blind, Placebo-controlled, Parallel-group, Comparative, Phase III Study to Evaluate the Efficacy and Safety of Nuvastatic® 300mg Capsule in Reducing Cancer-Tumor in Patients With Metastatic Colorectal Cancer Receiving Standard Chemotherapy.
  NCT07669454 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 6 locations
• A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
  NCT06750094 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 251 locations
• A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
  NCT06662786 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 238 locations
• A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer
  NCT06686576 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
  NCT07549412 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 34 locations
• A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
  NCT05253651 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 366 locations
• A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients
  NCT06497985 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
  NCT07525206 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 35 locations
• A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
  NCT07221357 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 283 locations
• AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer
  NCT06951503 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients
  NCT05797467 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Adjuvant FOLFIRI Based-chemotherapy After Resection of CLM Responding to Preoperative FOLFIRI
  NCT06501482 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal Cancer
  NCT06520683 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer
  NCT05179889 · Phase: Phase 2, Phase 3 · Ages: 20 Years to 75 Years · Sex: All (male and female) · 1 location
• Bevacizumab-based Chemotherapy Adapted to Bevacizumab Pharmacokinetics in 1st-line Treatment
  NCT06642844 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 4 locations
• Bovine Reinforcement in Stomach, Colorectal and Lung Operation
  NCT06968221 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• COLLISION RELAPSE Trial
  NCT05861505 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Chemopreventive Effect of Combination of Celecoxib and Metformin in Patients With Familial Adenomatous Polyposis
  NCT06545526 · Phase: Phase 3 · Ages: 20 Years to 55 Years · Sex: All (male and female) · 1 location
• Circulating Tumor DNA Methylation Guided Postoperative Adjuvant Chemotherapy for High-risk Stage II/III Colorectal Cancer
  NCT05954078 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
  NCT05174169 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1066 locations
• CompariSon Between the EuroPeAn and Japanese pathologiCal InvEstigation for Colon Cancer (SPACE)
  NCT06119867 · Phase: Phase 3 · Ages: No age limits stated · Sex: All (male and female) · 1 location
• Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC
  NCT05768503 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 12 locations
• Comparison of Transanal Irrigation and Glycerol Suppositories in Treatment of Low Anterior Resection Syndrome
  NCT04087421 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer
  NCT07389265 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 41 locations
• Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases
  NCT04687631 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• DEBIRI Plus Chemotherapy vs. Chemotherapy Alone in Colorectal Cancer Liver Metastases
  NCT06555003 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
  NCT05770102 · Phase: Phase 2, Phase 3 · Ages: No age limits stated · Sex: All (male and female) · 54 locations
• DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
  NCT05786716 · Phase: Phase 2, Phase 3 · Ages: 12 Years and older · Sex: All (male and female) · 27 locations
• DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
  NCT05768178 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 16 locations
• DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
  NCT07440290 · Phase: Phase 2, Phase 3 · Ages: 1 Year and older · Sex: All (male and female) · 27 locations
• DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer
  NCT06275958 · Phase: Phase 3 · Ages: 70 Years and older · Sex: All (male and female) · 36 locations
• Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Without Concurrent Surufatinib in Neoadjuvant Therapy for Mid-to-low Localized Rectal Cancer of High-risk Criteria
  NCT07505472 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
  NCT06008119 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Efficacy of Hyperthermic Intraperitoneal Chemotherapy
  NCT04861558 · Phase: Phase 3 · Ages: 18 Years to 79 Years · Sex: All (male and female) · 5 locations
• Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon Cancer
  NCT06783491 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Endoscopic Therapy Or Surgery for Early Colon Cancer
  NCT06940947 · Phase: Phase 3 · Ages: No age limits stated · Sex: All (male and female) · 1 location
• Evaluating Novel Therapies in ctDNA Positive GI Cancers
  NCT05482516 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors
  NCT07018869 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 384 locations
• FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.
  NCT06733038 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 24 locations
• FOLICOLOR TRIAL: Following Therapy Response Through Liquid Biopsy in Metatstatic Colorectal Cancer Patients
  NCT07558083 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer
  NCT06441565 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer
  NCT07722494 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer
  NCT03803553 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Improving Functional Outcomes and Quality of Life in Patients With Rectal Cancer After Surgery With Intensified Follow-up & Surveillance
  NCT06936774 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• Induction Chemotherapy for Locally Recurrent Rectal Cancer
  NCT04389086 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 14 locations
• Interest of Early Erectile Rehabilitation With Sildenafil After Radiotherapy and Proctectomy for Rectal Cancer
  NCT06123156 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: Male · 14 locations
• Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer
  NCT06509126 · Phase: Phase 3 · Ages: 18 Years to 100 Years · Sex: All (male and female) · 1 location
• Intraoperative Indocyanine Green Fluorescence Angiography in Colorectal Surgery to Prevent Anastomotic Leakage
  NCT05168839 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 32 locations
• Investigate the Efficacy of Chemotherapy in Patients With Positive ctDNA After Surgery and Adjuvant Chemotherapy for a Stage III Colorectal Cancer
  NCT06197425 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Localized Treatment Versus Palliative Chemotherapy in CRC Patients With 10 or More CRLM
  NCT06208371 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Mebendazole as Adjuvant Treatment for Colon Cancer
  NCT03925662 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Megestrol Acetate in Improving Neoadjuvant Chemotherapy-Related Weight Loss in Locally Advanced CRC
  NCT06998758 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Modulated Electro-Hyperthermia in Combination With Multimodal Therapy for Locally Advanced Rectal Cancer
  NCT07372300 · Phase: Phase 3 · Ages: 20 Years and older · Sex: All (male and female) · 1 location
• NALIRIFOX Plus Targeted Therapy Versus FOLFOX Plus Targeted Therapy as First-line Treatment for Metastatic Colorectal Cancer
  NCT07309289 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer
  NCT07528209 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Neoadjuvant Chemotherapy With PD-1 Inhibitors Combined With SIB-IMRT in the Treatment of Locally Advanced Rectal Cancer
  NCT06017583 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Neoadjuvant Chemotherapy for Obstructive Colon cancER First Treated by cOlostomy
  NCT06107920 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 28 locations
• Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer
  NCT06205485 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 113 locations
• Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers
  NCT05194878 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients
  NCT06280495 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Node-Sparing Short-Course Radiotherapy Plus Chemotherapy, Bevacizumab and PD-1 Inhibitor in Metastatic pMMR/MSS Colorectal Cancer (MODIFI-CRC)
  NCT06958419 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Node-Sparing Short-Course Radiotherapy Sequential Chemotherapy and PD-1 Inhibitor for Mid/Low pMMR/MSS Rectal Cancer (MODIFI-RC-II)
  NCT06958432 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Non Inferiority Study of Preoperative Chemotherapy Without Pelvic Irradiation for Rectal Cancer
  NCT03875781 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer
  NCT06226857 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 3 locations
• PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer
  NCT05236972 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Personalising and Refining Neo-adjuvant Chemotherapy in Locally Advanced but Resecable Colon Cancer in the Elderly of 70 Years Old or More
  NCT06293625 · Phase: Phase 3 · Ages: 70 Years and older · Sex: All (male and female) · 1 location
• Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis
  NCT06950385 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 29 locations
• Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCA
  NCT06207981 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 114 locations
• Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
  NCT07228832 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 166 locations
• Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12)
  NCT05534087 · Phase: Phase 3 · Ages: 19 Years to 75 Years · Sex: All (male and female) · 13 locations
• Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)
  NCT05008809 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 79 locations
• Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer
  NCT04495088 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma
  NCT05752136 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Prophylactic Mesh Placement During Stoma Closure After Low Anterior Resection
  NCT05939687 · Phase: Phase 3 · Ages: 18 Years to 85 Years · Sex: All (male and female) · 1 location
• Prospectively Randomized Control Clinical Trial of FOLFOXIRI Preoperative Chemotherapy Alone on Rectal Cancer in Local Advance Comparing to Oral Capecitabine Combined With Long-term Radiation
  NCT03671252 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• Protective Role of Alpha-Lipoic Acid in Chemotherapy-Induced Mucositis
  NCT07736495 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Randomizing Two Radiotherapy Boost Options to Avoid Rectal Cancer Surgery
  NCT03051464 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 4 locations
• Reducing Inflammatory Syndrome in Surgery - Colorectal (RISIS-CR) Trial
  NCT06646809 · Phase: Phase 3 · Ages: 45 Years and older · Sex: All (male and female) · 4 locations
• Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases
  NCT05794971 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer
  NCT05462613 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 16 locations
• SBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases
  NCT06794086 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC
  NCT07549399 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Sacituzumab Govitecan in Metastatic Colorectal Cancer
  NCT06243393 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Sintilimab Versus Mitomycin in Combination With Capecitabine and IMRT for Limited-stage Anal Squamous Cell Carcinoma
  NCT07692152 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• Standard Dose Versus High Dose of Radiotherapy in Rectal Preservation With Chemo-radiotherapy in Rectal Cancer Patients
  NCT04095299 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma
  NCT04749108 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 30 locations
• Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
  NCT05855200 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 266 locations
• Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)
  NCT07702032 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)
  NCT07775287 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
  NCT06252649 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 291 locations
• Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)
  NCT07219238 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Sulfasalazine in Patients With Metastatic Colorectal Cancer
  NCT06134388 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Surgery Plus Chemo Versus Chemoradiotherapy Followed by Surgery Plus Chemo for Locally Recurrent Rectal Cancer
  NCT04288999 · Phase: Phase 3 · Ages: 20 Years to 80 Years · Sex: All (male and female) · 45 locations
• Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
  NCT07222800 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 308 locations
• Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver
  NCT02885753 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 49 locations
• Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
  NCT05863195 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 62 locations

Showing 100 of 114 recruiting trials.

Common questions

What does Phase 3 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.